VivoSeq
Respiratory

Chronic Lung Disease

17

Pipeline Programs↗

2

Active Trials↗

10

Companies Involved↗

Chronic Lung Disease is an emerging landscape with 17 programs across 10 companies. The most active players are Bayer, Lee's Pharmaceutical Limited, Boehringer Ingelheim. 2 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

6/100

Mech. Concentration

22/100

Completion Rate

92/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

Phase 1L

Lee's Pharmaceutical Limited

1 program

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

3 programs

Phase 3P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3V

Viatris Specialty LLC

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

19

clinical trials

Completed12 · 63%
Unknown status4 · 21%
Active, not recruiting1 · 5%
Terminated1 · 5%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

19 trials

Recombinant Surfactant Protein D (rfhSP-D) to Prevent Neonatal Chronic Lung Disease
Active, not recruiting·UUniversity College, London·Phase 1·NCT05898633·24 enrolled
Prospective Study of Antimicrobial RESIstance in Chronic Lung DiseasE
Not yet recruiting·IImperial College London·N/A·NCT07646691·170 enrolled
Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
Completed·UUniversity of Colorado, Denver·Phase 3·NCT00006401·793 enrolled
Inhaled Beclomethasone to Prevent Chronic Lung Disease
Completed·National Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000576
Study to Characterize Lung Deposition, Pharmacokinetics, Safety and Tolerability of Single Inhalations of Radiolabeled Ciprofloxacin Dry Powder in Healthy Subjects and Patients With Chronic Lung Diseases
Completed·Bayer logoBayer·Phase 1·NCT01538667·24 enrolled
Efficacy of Clarithromycin Treatment in Prevention of Chronic Lung Disease in Premature Infants
Completed·ZZekai Tahir Burak Women's Health Research and Education Hospital·Phase 4·NCT01326611·273 enrolled
The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease
Completed·TThe University of Texas Health Science Center, Houston·N/A·NCT02544984·60 enrolled
Safety and Efficacy Study of Nitric Oxide for Inhalation on Chronic Lung Disease in Premature Babies
Completed·MMallinckrodt·Phase 3·NCT00551642·800 enrolled
Examining the Use of Non-Invasive Inhaled Nitric Oxide to Reduce Chronic Lung Disease in Premature Newborns
Completed·UUniversity of Colorado, Denver·Phase 2·NCT00955487·124 enrolled
To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 3·NCT02085161·304 enrolled
Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children
Completed·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT02426112·347 enrolled
The Effect of Sildenafil in Preterm Infants With Evolving Chronic Lung Disease
Completed·—·Phase 3·NCT00431418·20 enrolled
Autologous Cellular Therapy With PRP-PC in Chronic Lung Diseases: An Observational Study LI-004
Completed·HH-CYTE·N/A·NCT05562843·150 enrolled
Treatment Outcome Between Mycobacterium Abscessus Infection in Chronic Lung Disease and Acquired Interferon-gamma Autoantibody Syndrome
Completed·KKing Chulalongkorn Memorial Hospital·N/A·NCT05354583·36 enrolled
Minimal Breathing Support and Early Steroids to Prevent Chronic Lung Disease in Extremely Premature Infants (SAVE)
Terminated·NNICHD Neonatal Research Network·Phase 3·NCT00005777·220 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)